Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2019 Nov 20;16(11):e1002985. doi: 10.1371/journal.pmed.1002985

Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007–2015: A registry-based cohort study

Anders Jans 1, Ingmar Näslund 1, Johan Ottosson 1, Eva Szabo 1, Erik Näslund 2, Erik Stenberg 1,*
Editor: Kirsi H Pietiläinen3
PMCID: PMC6867594  PMID: 31747392

Abstract

Background

Although bariatric surgery is an effective treatment for type 2 diabetes (T2D) in patients with morbid obesity, further studies are needed to evaluate factors influencing the chance of achieving diabetes remission. The objective of the present study was to investigate the association between T2D duration and the chance of achieving remission of T2D after bariatric surgery.

Methods and findings

We conducted a nationwide register-based cohort study including all adult patients with T2D and BMI ≥ 35 kg/m2 who received primary bariatric surgery in Sweden between 2007 and 2015 identified through the Scandinavian Obesity Surgery Registry. The main outcome was remission of T2D, defined as being free from diabetes medication or as complete remission (HbA1c < 42 mmol/mol without medication). In all, 8,546 patients with T2D were included. Mean age was 47.8 ± 10.1 years, mean BMI was 42.2 ± 5.8 kg/m2, 5,277 (61.7%) were women, and mean HbA1c was 58.9 ± 17.4 mmol/mol. The proportion of patients free from diabetes medication 2 years after surgery was 76.6% (n = 6,499), and 69.9% at 5 years (n = 3,765). The chance of being free from T2D medication was less in patients with longer preoperative duration of diabetes both at 2 years (odds ratio [OR] 0.80/year, 95% CI 0.79–0.81, p < 0.001) and 5 years after surgery (OR 0.76/year, 95% CI 0.75–0.78, p < 0.001). Complete remission of T2D was achieved in 58.2% (n = 2,090) at 2 years, and 46.6% at 5 years (n = 681). The chance of achieving complete remission correlated negatively with the duration of diabetes (adjusted OR 0.87/year, 95% CI 0.85–0.89, p < 0.001), insulin treatment (adjusted OR 0.25, 95% CI 0.20–0.31, p < 0.001), age (adjusted OR 0.94/year, 95% CI 0.93–0.95, p < 0.001), and HbA1c at baseline (adjusted OR 0.98/mmol/mol, 95% CI 0.97–0.98, p < 0.001), but was greater among males (adjusted OR 1.57, 95% CI 1.29–1.90, p < 0.001) and patients with higher BMI at baseline (adjusted OR 1.07/kg/m2, 95% CI 1.05–1.09, p < 0.001). The main limitations of the study lie in its retrospective nature and the low availability of HbA1c values at long-term follow-up.

Conclusions

In this study, we found that remission of T2D after bariatric surgery was inversely associated with duration of diabetes and was highest among patients with recent onset and those without insulin treatment.


Erik Stenberg and colleagues investigate the association between duration of Type 2 diabetes and remission from Type 2 diabetes after bariatric surgery.

Author summary

Why was this study done?

  • Bariatric surgery is an effective treatment for type 2 diabetes in obese patients.

  • Previous studies have identified several factors affecting the chance of diabetes remission after bariatric surgery, such as age, HbA1c, insulin therapy, and diabetes duration.

  • The main purpose of the study was to analyze the relationship between preoperative diabetes duration and the likelihood of achieving diabetes remission after bariatric surgery in a large nationwide patient population.

What did the researchers do and find?

  • The registry-based nationwide study included 8,546 patients with type 2 diabetes who underwent bariatric surgery in Sweden between 2007 and 2015.

  • In total, complete diabetes remission was achieved in 58.2% of patients after 2 years and 46.6% after 5 years.

  • In this study, we found that remission of type 2 diabetes after bariatric surgery was inversely associated with duration of diabetes and was highest among patients with recent onset and those without insulin treatment.

What do these findings mean?

  • The relationship between preoperative diabetes duration and chance of diabetes remission is valuable in analyzing the potential benefit compared to risk related to bariatric surgery, and can therefore be used to prioritize for surgery those patients who are most likely to achieve diabetes remission.

Introduction

Since 1980, the average body mass index (BMI) has risen globally, yielding a prevalence of obesity as high as 10.8% in men and 14.9% in women [1,2]. In several countries, the prevalence may approach or even reach beyond 50% of the adult population [3]. Obesity is a strong risk factor for developing type 2 diabetes (T2D) [4]. Consequently, T2D contributes greatly to the overall burden of disease [5]. Compared to nonsurgical treatment, bariatric surgery provides a more effective way to achieve long-term weight loss in obese individuals [6], and increases overall survival in this patient group [6]. Obese patients with T2D have a good chance of achieving long-term T2D remission after surgery [711], although some patients who initially remit later relapse [7,12]. The duration of diabetes prior to surgery, glycemic control, insulin use, age, and postoperative weight loss have previously been suggested as factors influencing the chance of achieving remission of T2D after bariatric surgery [9,1116]. These studies generally comprise small samples, some over rather short periods of time. Larger studies are thus needed to ascertain which factors are associated with diabetes remission.

The aim of the present study was to evaluate the impact of preoperative duration of diabetes and other factors on the chance of achieving diabetes remission after bariatric surgery.

Methods

This study was a retrospective cohort study on prospectively collected data from the Scandinavian Obesity Surgery Registry (SOReg). The registry was launched in 2007 and covers virtually all bariatric surgical procedures in Sweden, with very high registration validity [17]. All patients who received primary gastric bypass or sleeve gastrectomy surgery between January 1, 2007, and December 31, 2015, and registered in SOReg were considered for inclusion in the study. Only patients with T2D as defined by the American Diabetes Association were included [4]. Although an original study plan was decided on by the authors, it was not documented beforehand. After the study began, percentage total weight loss (%TWL) was changed to percentage excess BMI loss (%EBMIL) in the multivariable analysis as a response to review; no other changes were made to the original plan.

By using the Swedish personal identification number, unique to each citizen, the SOReg data file was linked to the Swedish National Patient Register, the Swedish Population Register (for mortality data), the Swedish Prescribed Drug Register, and Statistics Sweden. Information on baseline characteristics, surgery, and follow-up were based on data from SOReg. Since cardiovascular comorbidity and previous pulmonary embolus/deep venous thrombosis are not obligatory variables in SOReg, data on these conditions were based on combined data from the Swedish National Patient Register and SOReg. Preoperative duration of diabetes was based on a combination of data from SOReg, the National Patient Registries and the Swedish Prescribed Drug Register. Data on specific pharmaceutical treatment for diabetes were based on data from SOReg and the Swedish Prescribed Drug Register. Information on education was based on patient-specific data from Statistics Sweden.

Procedures

The surgical method for gastric bypass is highly standardized in Sweden, with 99% being an antecolic/antegastric gastric bypass procedure with a small gastric pouch [18]. The sleeve gastrectomy is less standardized, but routinely performed using a 32–36 Fr bougie with the gastric division starting 5 cm from the pylorus and ending 1 cm from the angle of His. Perioperative care closely follows the Enhanced Recovery After Surgery guidelines, with early mobilization, routine thromboprophylaxis, and start of oral fluids on the day of surgery [19].

Outcomes and definitions

The main outcome was remission of diabetes 2 and 5 years after surgery. To allow comparison with previous studies, this was defined both as being without medication at these points in time (including a time frame of ±6 months) and achieving complete remission of diabetes.

Complete remission of diabetes was defined as a glycosylated hemoglobin A1c (HbA1c) < 42 mmol/mol (6.0%) without medical treatment. Partial remission of diabetes was defined as HbA1c of 42–48 mmol/mol (6.0%–6.5%) without medical treatment, in accordance with the recommendations of the American Society for Metabolic and Bariatric Surgery [20]. Controlled diabetes was defined as HbA1c < 48 mmol/mol (<6.5%) with medical treatment.

Comorbidity was defined as a medical condition requiring pharmaceutical treatment, or continuous positive airway pressure treatment in the case of sleep apnea. Cardiovascular comorbidity was defined as a history of ischemic heart disease, angina pectoris, cardiomyopathy, cardiac failure, or arrhythmic heart disease.

Postoperative weight loss was presented as change in BMI (ΔBMI = initial BMI − postoperative BMI), percentage total weight loss (%TWL = 100 × weight loss/preoperative weight), and percentage excess BMI loss (%EBMIL = 100 × [initial BMI − postoperative BMI]/[initial BMI − 25]). Postoperative complications were classified according to the Clavien–Dindo classification, and having a postoperative complication was defined as Clavien–Dindo ≥ 1. Postoperative complications graded ≥3b were considered serious complications [21]. Since more specific classification of postoperative complications was made obligatory in SOReg starting January 1, 2010, only patients operated on from this date onwards were included in the analysis of serious postoperative complications.

Statistics

Baseline data (before surgery) and follow-up data are presented as numbers of individuals (n) with percentages of patients for categorical values, mean ± standard deviation (SD) for continuous variables assuming normal distribution, and median ± interquartile range (IQR) for continuous variables not assuming normal distribution. Univariable logistic regression analyses were conducted to evaluate risks related to the major endpoints of the study. The correlation between diabetes duration and remission of diabetes was evaluated using the Spearman correlation test. Based on previous studies and plausible impact of preoperatively available factors, diabetes duration, insulin treatment, BMI, age, sex, HbA1c, education, %EBMIL, and surgical method were incorporated in the multivariable logistic regression analyses [22,23]. Missing data were handled by listwise deletion. p < 0.05 was considered to represent statistical significance.

SPSS Statistics version 25 (IBM, Armonk, New York, US) was used for all analyses.

Ethics

The study was approved by the Regional Ethics Committee in Stockholm (Dnr 2013/535-31/5, 2014/1639-32, and 2017/857-32) and conducted in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments. No written consent was obtained from the study participants. However, in accordance with Swedish legislation, all participants were informed of the research and quality registry and that the data would be used in clinical research, giving the patients the right to decline participation.

Results

During the inclusion period, 8,546 patients with T2D according to the definition of the American Diabetes Association were identified in SOReg. Two years after surgery, 57 patients had died, leaving 8,489 (99%) patients available for analysis of pharmaceutical usage. After exclusion of patients who died prior to the 5-year follow-up (n = 178) and patients who did not reach this time point by the end of the study (n = 2,980), 5,388 patients were available for analyses on pharmaceutical use at 5 years. HbA1c was available at 2 years for 3,594 patients (42% of patients reaching the 2-year follow-up) and at 5 years for 1,460 patients (27% of patients reaching the 5-year follow-up). Follow-up data on day 30 were available for 8,448 patients (99% of all patients) (Fig 1). Data on baseline characteristics for the study group are presented in Table 1.

Fig 1. Study flowchart describing availability for analyses.

Fig 1

Table 1. Baseline characteristics.

Characteristic Missing data, n (%) Mean ± SD or n (%)
BMI, kg/m2 0 (0.0%) 42.2 ± 5.8
Age, years 0 (0.0%) 47.8 ± 10.1
Sex 0 (0.0%)
  Female 5,277 (61.7%)
  Male 3,269 (38.3%)
Comorbidity
  Sleep apnea 0 (0.0%) 1,607 (18.8%)
  Cardiovascular comorbidity 0 (0.0%) 972 (11.4%)
  Hypertension 0 (0.0%) 4,810 (56.3%)
  Dyslipidemia 0 (0.0%) 2,679 (31.3%)
  Dyspepsia/gastroesophageal reflux disease 0 (0.0%) 1,087 (12.7%)
  Depression 0 (0.0%) 1,405 (16.4%)
  Previous pulmonary embolus/deep venous thrombosis 0 (0.0%) 219 (2.6%)
Glycosylated hemoglobin A1c, mmol/mol 1,134 (13.3%) 58.9 ± 17.4
Education 59 (0.7%)
  Primary education (≤9 years) 1,691 (19.9%)
  Secondary education (10–12 years) 5,027 (59.2%)
  Higher education ≤3 years 898 (10.6%)
  Higher education >3 years 871 (10.3%)

Surgical data

A total of 8,112 patients underwent a gastric bypass procedure (94.9%), and 434 a sleeve gastrectomy (5.1%). A laparoscopic procedure was completed in 8,171 operations (95.6%), 111 operations were converted to open surgery (1.3%), and a primary open procedure was performed in 264 operations (3.1%). The median hospital stay was 2 days (IQR 1–2 days). A postoperative complication (Clavien–Dindo ≥ 1) occurred within 30 days after 863 operations (10.2%). A serious postoperative complication occurred within 30 days after 241 operations (3.5%). Mean BMI loss at 2 years was 11.9 ± 4.6 kg/m2, %TWL 28.1% ± 9.2%, and %EBMIL 72.7% ± 24.7%. Mean BMI loss at 5 years was 10.7 ± 4.7 kg/m2, %TWL 25.2% ± 9.6%, and %EBMIL 64.4% ± 25.6%.

Impact on diabetes medication

At baseline, 4,192 patients (49.1%) received oral medical treatment alone for diabetes, 453 received insulin alone (5.3%), 14 received a GLP-1 analogue alone (0.2%), and 1,973 received a combination of oral treatment and insulin (23.1%). The remaining 1,914 patients received non-pharmacological management only for their diabetes (22.5%).

Two years after surgery, 1,990 patients (23.4%) received pharmacological treatment for diabetes: 1,328 received oral medical treatment alone for diabetes (15.6%), 228 received insulin alone (2.7%), 19 received a GLP-1 analogue alone (0.2%), and 415 received a combination of oral treatment and insulin (4.9%).The remaining 6,499 did not receive medical treatment for diabetes 2 years after surgery (76.6%). The chance of being free of diabetes medication was less with longer preoperative duration of diabetes (odds ratio [OR] 0.80/year, 95% CI 0.79–0.81, p < 0.001; Spearman coefficient −0.43, p < 0.001) (Table 2 and Fig 2).

Table 2. Numbers free from medical treatment 2 and 5 years after surgery.

Diabetes duration, years n (%) free from medical treatment at follow-up
2 years 5 years
<1 2,473 (96.1%) 1,535 (94.2%)
1 899 (86.7%) 553 (83.0%)
2 674 (82.9%) 404 (75.0%)
3 549 (75.6%) 322 (66.1%)
4 437 (74.3%) 252 (62.6%)
5 407 (69.3%) 252 (59.0%)
6–7 469 (58.0%) 223 (43.0%)
8–9 270 (51.5%) 95 (34.5%)
10–12 187 (44.0%) 76 (32.1%)
13–15 61 (34.3%) 29 (33.0%)
16–20 49 (35.8%) 17 (22.1%)
21–25 21 (32.3%) 6 (17.1%)
≥26 3 (10.7%) 1 (7.7%)

Fig 2. Proportion of patients free from medication at 2 and 5 years after surgery.

Fig 2

Five years after surgery, 1,623 patients (30.1%) received pharmacological treatment for diabetes: 1,095 received oral medical treatment alone for diabetes (20.3%), 152 received insulin alone (3.0%), 24 received a GLP-1 analogue alone (0.4%), and 342 received a combination of oral treatment and insulin (6.4%). The remaining 3,765 did not receive medical treatment for diabetes 5 years after surgery (69.9%). As at 2 years, the chance of being free of diabetes medication 5 years after surgery was less with longer preoperative duration of diabetes (OR 0.76/year, 95% CI 0.75–0.78, p < 0.001; Spearman coefficient −0.48, p < 0.001) (Table 2 and Fig 2).

Diabetes remission

Two years after surgery, 2,090 patients had complete remission of their diabetes (58.2%), 429 patients achieved partial remission (11.9%), 428 had controlled diabetes on medication (11.9%), and 647 patients (7.6%) still had a HbA1c ≥ 48 mmol/mol on pharmacological treatment (Fig 3). The chance of achieving complete remission was less the longer the preoperative duration of diabetes (OR 0.78/year, 95% CI 0.76–0.79, p < 0.001; Spearman coefficient −0.46, p < 0.001).

Fig 3. Stacked histogram of 2-year remission in relation to duration of diabetes.

Fig 3

Five years after surgery, 681 patients had complete remission of their diabetes (46.6%), 175 patients had partial remission (12.0%), 188 had controlled diabetes on medication (12.9%), and 416 patients (28.5%) still had a HbA1c > 48 mmol/mol on pharmacological treatment (Fig 4). The chance of achieving complete remission was still less the longer the preoperative duration of diabetes (OR 0.77/year, 95% CI 0.74–0.80, p < 0.001; Spearman coefficient –0.44, p < 0.001).

Fig 4. Stacked histogram of 5-year remission in relation to duration of diabetes.

Fig 4

Multivariable analysis

Of the selected preoperative factors potentially influencing diabetes remission, longer duration of diabetes, higher baseline HbA1c, high age, and insulin treatment were all associated with lower remission rates 2 years after surgery. Higher BMI, higher excess BMI loss, and male sex in patients with T2D were associated with higher remission rates. Higher education and gastric bypass were associated with better chance of achieving diabetes remission in the univariable analyses, but the associations did not remain statistically significant in the multivariable analyses (Table 3).

Table 3. Odds ratios (ORs) for reaching complete diabetes remission 2 years after surgery.

 Characteristic Unadjusted OR (95% CI) Adjusted OR (95% CI)1 Adjusted p-Value1
Preoperative diabetes duration 0.78 (0.76–0.79) 0.87 (0.85–0.89) <0.001
Baseline HbA1c 0.96 (0.95–0.97) 0.98 (0.97–0.98) <0.001
Insulin treatment at baseline 0.15 (0.12–0.16) 0.25 (0.20–0.31) <0.001
Percentage excess BMI loss 1.02 (1.01–1.02) 1.03 (1.02–1.03) <0.001
Age 0.94 (0.93–0.95) 0.94 (0.93–0.95) <0.001
Preoperative BMI 1.06 (1.04–1.07) 1.07 (1.05–1.09) <0.001
Sex
  Female Reference Reference Reference
  Male 0.89 (0.77–1.02) 1.57 (1.29–1.90) <0.001
Education
  Primary education (≤9 years) 0.77 (0.65–0.92) 0.96 (0.76–1.22) 0.747
  Secondary education (10–12 years) Reference Reference Reference
  Higher education ≤3 years 1.07 (0.86–1.34) 1.15 (0.86–1.55) 0.353
  Higher education >3 years 1.27 (1.10–1.60) 1.26 (0.94–1.70) 0.126
Surgical method
  Gastric bypass Reference Reference Reference
  Sleeve gastrectomy 0.64 (0.47–0.88) 0.72 (0.48–1.10) 0.129

1Multivariable logistic regression including all factors listed in the table.

Discussion

In the present study, a strong negative correlation between preoperative duration of T2D and the chance of diabetes remission after bariatric surgery was seen. The negative correlation was linear even over very long diabetes duration, supporting the results of previous studies [9,1116]. Other factors of importance were insulin treatment and baseline HbA1c as markers of severity of disease, age, sex, and postoperative weight loss.

Remission rate depends on the definition used to define diabetes remission. With the current definition of complete remission, the remission rate in the study cohort was comparable to that reported in previous studies [9,13]. Thus, our results support the already established position of bariatric surgery as an important tool in the treatment of T2D in patients with morbid obesity [10]. However, the benefits of bariatric surgery appear to be greatest amongst patients with more recent onset of T2D and those with less severe disease.

Although the mechanisms behind the metabolic effects of bariatric surgery are complex and incompletely understood, they appear to be mediated by a combination of weight-loss-dependent and -independent factors, resulting in improved insulin sensitivity and improved pancreatic beta-cell function [2427]. Patients with longer duration of T2D are more likely to have reduced beta-cell function and secretory capacity. Although this group of patients will still benefit from the reduction in insulin resistance resulting from bariatric surgery, patients with reduced beta-cell function are less likely to achieve complete remission. This hypothesis is supported by the lower remission rates among patients with poorer glycemic control and insulin dependence prior to surgery, as seen in both the present study and previous studies [1214]. Although higher preoperative HbA1c does not necessarily correlate to reduced beta-cell function, it indicates poorer glycemic control and greater severity of disease, factors known to reduce the chance of diabetes remission [12,23]. Preoperative insulin treatment, on the other hand, indicates significantly reduced beta-cell function that may not fully respond to the increase in incretin secretion after bariatric surgery. The strong negative correlation between preoperative insulin treatment and chance of achieving complete diabetes remission is well supported by reports from previous studies [12,15].

Age was found to be negatively associated with diabetes remission. Aung et al. also reported a negative correlation between age and the chance of diabetes remission [14]. In their study, patients with late onset of diabetes had a lower chance of durable diabetes remission after bariatric surgery [14]. Furthermore, older patients are known to lose less weight than younger patients after bariatric surgery [28], a factor also associated with reduced chance of achieving complete remission. A combination of a slightly different metabolic profile with poorer weight loss among older patients may well explain the negative association between age and diabetes remission. The influence of sex on diabetes remission is less clear. With the higher proportion of women in the study, it is possible that men with T2D represented a different subgroup than women with T2D due to different fat distribution. Indeed, the fat distribution pattern more often seen in men is strongly related to metabolic complications of obesity [29]. The weight loss after bariatric surgery could thus have higher metabolic impact in patients with male fat distribution.

In the present study, higher preoperative BMI was associated with improved T2D remission rates in the univariable as well as the multivariable analyses. To our knowledge, this has not been reported in previous studies, possibly due to smaller patient numbers. Although no explicit explanation can be provided from the results of this study, it could be that T2D has different characteristics depending on the degree of obesity, where patients with a high BMI have a greater degree of insulin resistance. In patients with a lower BMI, genetic factors and reduced beta-cell function could play a greater role. Furthermore, patients with a high BMI tend to lose more weight after bariatric surgery [30], and thus experience a more significant weight-dependent metabolic effect of surgery.

Consistent with previous studies, gastric bypass appeared to be associated with higher rates of diabetes remission compared to sleeve gastrectomy in the unadjusted analysis [9,10]. Previous studies have reported similar effects on glucose homeostasis and incretin levels when comparing these 2 methods [31]. A plausible explanation may be the difference in postoperative weight loss seen in this and previous studies. However, the present study was not designed to compare the efficacy of the 2 methods, so this result should be viewed with caution. Further randomized trials comparing the effectiveness of the methods are still needed.

Strengths and limitations

Despite the strengths of this study—i.e., the large number of patients, nationwide data, and the high quality of data, allowing estimation of treatment effects for bariatric surgical patients with T2D—there are limitations that must be acknowledged. The major limitation lies in the retrospective nature of the study. By using clinical registries, the study was limited to the variables and definitions already specified by those registries. Some valuable clinical variables, e.g., C-peptide and behavioral patterns, could thus not be included. Furthermore, diabetes remission was defined based on prescribed drugs. Despite reaching adequate glucose control, patients are sometimes encouraged by healthcare providers to continue certain diabetes drugs such as metformin [32]. This would give the impression that medication was still necessary, i.e., no remission, resulting in underestimation of the diabetes remission rate. It is unlikely, however, that this influenced the major outcomes of the present study. Finally, consistent with previous reports, high follow-up rates are difficult to achieve outside of randomized clinical trials [33]. In the present study, HbA1c values were only available for 27% of patients at the 5-year follow-up, limiting analysis of long-term complete remission. However, the patterns of pharmaceutical usage and complete remission were very similar at the 2-year and 5-year follow-ups after surgery, consistent with previous studies.

Conclusion

Remission of T2D after bariatric surgery is negatively correlated to diabetes duration, with the highest rates among patients with more recent onset and less severe disease.

Supporting information

S1 STROBE checklist

(DOC)

Abbreviations

%EBMIL

percentage excess BMI loss

%TWL

percentage total weight loss

OR

odds ratio

SOReg

Scandinavian Obesity Surgery Registry

T2D

type 2 diabetes

Data Availability

Data cannot be shared publicly because of patient confidentiality under current Swedish legislation. Data are available from the Scandinavian Obesity Surgery Registry (contact via www.ucr.uu.se/soreg/) for researchers who meet the criteria for access to confidential data.

Funding Statement

This work was supported by grants from the Örebro Region County Council (AJ, grant number: OLL-915571; ESt grant number:OLL-884791), the Bengt Ihre Foundation (ESt), Stockholm County Council (EN), SRP Diabetes (EN) and the NovoNordisk Foundation (EN). The funders had no role in study design, data Collection and alaysis, decision to publish, or preparation of the manuscript

References

  • 1.Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67. 10.1016/S0140-6736(10)62037-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377–96. 10.1016/S0140-6736(16)30054-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. 10.1016/S0140-6736(14)60460-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90. [DOI] [PubMed] [Google Scholar]
  • 5.Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49. 10.1016/j.diabres.2013.11.002 [DOI] [PubMed] [Google Scholar]
  • 6.Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34. 10.1111/joim.12012 [DOI] [PubMed] [Google Scholar]
  • 7.Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. 10.1001/jama.2014.5988 [DOI] [PubMed] [Google Scholar]
  • 8.Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85. 10.1056/NEJMoa1200111 [DOI] [PubMed] [Google Scholar]
  • 9.Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51. 10.1056/NEJMoa1600869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77. 10.2337/dc16-0236 [DOI] [PubMed] [Google Scholar]
  • 11.Backman O, Bruze G, Naslund I, Ottosson J, Marsk R, Neovius M, et al. Gastric bypass surgery reduces de novo cases of type 2 diabetes to population levels: a nationwide cohort study from Sweden. Ann Surg. 2019;269(5):895–902. 10.1097/SLA.0000000000002983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93–102. 10.1007/s11695-012-0802-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Panunzi S, Carlsson L, De Gaetano A, Peltonen M, Rice T, Sjostrom L, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39(1):166–74. 10.2337/dc15-0575 [DOI] [PubMed] [Google Scholar]
  • 14.Aung L, Lee WJ, Chen SC, Ser KH, Wu CC, Chong K, et al. Bariatric surgery for patients with early-onset vs late-onset type 2 diabetes. JAMA Surg. 2016;151(9):798–805. 10.1001/jamasurg.2016.1130 [DOI] [PubMed] [Google Scholar]
  • 15.Blackstone R, Bunt JC, Cortes MC, Sugerman HJ. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis. 2012;8(5):548–55. 10.1016/j.soard.2012.05.005 [DOI] [PubMed] [Google Scholar]
  • 16.Brethauer SA, Aminian A, Romero-Talamas H, Batayyah E, Mackey J, Kennedy L, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36. 10.1097/SLA.0b013e3182a5034b [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hedenbro JL, Naslund E, Boman L, Lundegardh G, Bylund A, Ekelund M, et al. Formation of the Scandinavian Obesity Surgery Registry, SOReg. Obes Surg. 2015;25(10):1893–900. 10.1007/s11695-015-1619-5 [DOI] [PubMed] [Google Scholar]
  • 18.Olbers T, Lonroth H, Fagevik-Olsen M, Lundell L. Laparoscopic gastric bypass: development of technique, respiratory function, and long-term outcome. Obes Surg. 2003;13(3):364–70. 10.1381/096089203765887679 [DOI] [PubMed] [Google Scholar]
  • 19.Thorell A, MacCormick AD, Awad S, Reynolds N, Roulin D, Demartines N, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg. 2016;40(9):2065–83. 10.1007/s00268-016-3492-3 [DOI] [PubMed] [Google Scholar]
  • 20.Brethauer SA, Kim J, El Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506. 10.1016/j.soard.2015.02.003 [DOI] [PubMed] [Google Scholar]
  • 21.Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. 10.1097/01.sla.0000133083.54934.ae [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Koliaki C, Liatis S, le Roux CW, Kokkinos A. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50 10.1186/s12902-017-0202-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Huang X, Liu T, Zhong M, Cheng Y, Hu S, Liu S. Predictors of glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass: a meta-analysis, meta-regression, and systematic review. Surg Obes Relat Dis. 2018;14(12):1822–31. 10.1016/j.soard.2018.08.027 [DOI] [PubMed] [Google Scholar]
  • 24.Purnell JQ, Johnson GS, Wahed AS, Dalla Man C, Piccinini F, Cobelli C, et al. Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia. 2018;61(5):1142–54. 10.1007/s00125-018-4553-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bradley D, Conte C, Mittendorfer B, Eagon JC, Varela JE, Fabbrini E, et al. Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest. 2012;122(12):4667–74. 10.1172/JCI64895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Jackness C, Karmally W, Febres G, Conwell IM, Ahmed L, Bessler M, et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell function in type 2 diabetic patients. Diabetes. 2013;62(9):3027–32. 10.2337/db12-1762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care. 2016;39(6):893–901. 10.2337/dc16-0145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chang WW, Hawkins DN, Brockmeyer JR, Faler BJ, Hoppe SW, Prasad BM. Factors influencing long-term weight loss after bariatric surgery. Surg Obes Relat Dis. 2019;15(3):456–61. 10.1016/j.soard.2018.12.033 [DOI] [PubMed] [Google Scholar]
  • 29.Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S57–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Seyssel K, Suter M, Pattou F, Caiazzo R, Verkindt H, Raverdy V, et al. A Predictive model of weight loss after Roux-en-Y gastric bypass up to 5 years after surgery: a useful tool to select and manage candidates to bariatric surgery. Obes Surg. 2018;28(11):3393–9. 10.1007/s11695-018-3355-0 [DOI] [PubMed] [Google Scholar]
  • 31.Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41. 10.1097/SLA.0b013e3181ae32e3 [DOI] [PubMed] [Google Scholar]
  • 32.Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. 10.2337/dc08-9025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Higa K, Ho T, Tercero F, Yunus T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis. 2011;7(4):516–25. 10.1016/j.soard.2010.10.019 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Adya Misra

10 Sep 2019

Dear Dr. Stenberg,

Thank you very much for submitting your manuscript "The impact of duration of diabetes on remission rates after bariatric surgery" (PMEDICINE-D-19-02752) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Oct 01 2019 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra,

Senior Editor

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

Title, please recast to include a study descriptor. Perhaps:

Association with bariatric surgery and the duration of type 2 diabetes in Sweden 2007-2015: a retrospective cohort study

Abstract – this is structured with 3 sections: Background, Methods and Findings and Conclusions and please ensure the final sentence of the Methods and Findings section includes a sentence on the limitations of the study.

Abstract – please include cities and some summary participant information such as age, sex, BMI, etc

Data – an author cannot be a point of contact – please find another contact point.

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

References in the main text – please use square brackets and remove superscript

Was written consent provided by participants?

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis—including those made in response to peer review comments—should be identified as such in the Methods section of the paper, with rationale.

Please provide a STROBE reporting guidelines (submitted as a Supp file and ensure paragraph and sections are used instead of page numbers – these will change in the event of publication.)

Comments from the reviewers:

Reviewer #1: I have read with great interest the paper by Jans et al. They have used the large Swedish registry data on bariatric surgeries, to answer the question that which factors contribute to remission of T2DM after surgically-induced weight loss. The study was well-designed and -written. I have only some very minor comments to it.

Abstract

At first read, it was slightly difficult to capture the concept of correlation in the sentence: "The chance of achieving complete remission correlated…" since there were both continuous (duration of diabetes, age, Hba1c) and dichotomous variables (insulin treatment) in the analyses. Can this be opened, e.g. by adding units after each OR.

Introduction

Obesity rates are low. Any data available for larger prevalences, which is the case in most countries?

Methods

Nro of patients in each operation type could belong to the methods, however if the authors wish, it can as well remain in the results section as it is now.

Results

A flow chart of the available patients would be useful. The percentages are hard to follow. For example in the sentence "5388 patients were available for analyses on pharmaceutical use at 5 years (98%)": What does the 98% represent?

Reviewer #2: Thanks for the chance to review this manuscript. This study verified that longer T2DM duration, insulin therapy prior to surgery, lower BMI were negative predictors to predict T2DM remission after RYGB/SG with a large sample size and longer follow-up period. Although these data from several registry systems was high-quality, some valuable clinical variables were missing, for instance, fasting C peptide.

Many previous studies have found T2DM duration, C peptide, age, BMI and insulin usage were powerful predictive factors, and thus the novelty of this study is limited. Additionally, during follow-up period, most patients were lost, which affected the credibility of the conclusions.

Reviewer #3: Due to the imbalanced effects of bariatric surgery on clinically improving metabolic disorders among patients, exploring the factors that affect surgery-induced benefits is quite necessary. In this study, the author provides convincing evidences with large sample size to support his conclusion that the remission of T2DM induced by bariatric surgery is negatively correlated to duration of diabetes and increases in patient with recent onset diabetes and those without insulin treatment. These findings are meaningful for clinician to make decision on treating T2DM by surgery, a treatment that, although effective, cause irreversible changes in patient's GI track.

However, as the author mentioned in the manuscript, the retrospective property of this study limits its significance, other variables among subjects such as distinct behaviors during as long as 5 years may also contribute to the uneven diabetic remission rate after surgery, which need to be further and deeply explored. Whereas the high-quality data and large sample size of this study still make it convincible, and it should be eligible to be published in Plos medicine.

Reviewer #4: I confine my remarks to statistical aspects of this paper. In general, these were fine, although I do wonder why the authors did not do a Cox proportional hazards survival analysis.

Some comments/suggestions:

Line 127-8 I think it would be better to use "proportion of excess weight". I am guessing that the people in the study varied a lot in how overweight they were. If a person is 100 kg overweight and another is 200 kg overweight and each loses 100 kg, it does not have the same effect. Maybe there is no good estimate of ideal weight, but even BMI (flawed though that is) could be used.

Table 1 - What about exactly 10 years of education? or exactly3 years of higher education?

Figures - stacked histograms are not a good method (see the work of William S. Cleveland). Line charts would be better with duration on the x axis, percent on the y axis and a line for each outcome.

Peter Flom

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 1

Adya Misra

23 Oct 2019

Dear Dr. Stenberg,

Thank you very much for re-submitting your manuscript "Association with duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: a registry-based cohort study" (PMEDICINE-D-19-02752R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

Our publications team (plosmedicine@plos.org) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU'VE RECEIVED THE PRODUCTION REQUIREMENTS.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.

We look forward to receiving the revised manuscript by Oct 30 2019 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

Please remove "association with" from the start of the title

Abstract “other important factors” – please be specific in text. In this case, specify or remove;

Author summary – please remove ‘obesity surgery’ as I don’t think this is an official term, is it?

- There are some "p<0.0001" in the abstract and results – please alter to <0.001, per house style

Line 221 – “4192 patients received oral treatment” please be specific, of what? And again line 226, please also correct anywhere else in the main text.

- "In this study, we found that ... was ..." at line 58, or similar (and around line 88)

- I'd go for "negatively [or "inversely"] associated" rather than "negatively correlated"

- square brackets needed for refs in the main text

Comments from Reviewers:

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Adya Misra

31 Oct 2019

Dear Dr. Stenberg,

On behalf of my colleagues and the academic editor, Dr. Kirsi H. Pietiläine, I am delighted to inform you that your manuscript entitled "Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: a registry-based cohort study" (PMEDICINE-D-19-02752R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer's (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to https://www.editorialmanager.com/pmedicine, log in, and click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

plosmedicine.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 STROBE checklist

    (DOC)

    Attachment

    Submitted filename: rebutal_plos.docx

    Data Availability Statement

    Data cannot be shared publicly because of patient confidentiality under current Swedish legislation. Data are available from the Scandinavian Obesity Surgery Registry (contact via www.ucr.uu.se/soreg/) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES